Chaoxin Xiao
YOU?
Author Swipe
View article: Trends, age shifts, and potential delayed peaks post-pandemic of early-onset brain and central nervous system cancers in individuals aged 20–49: a cross-sectional study
Trends, age shifts, and potential delayed peaks post-pandemic of early-onset brain and central nervous system cancers in individuals aged 20–49: a cross-sectional study Open
Background: Central nervous system (CNS) cancers are highly lethal and increasingly affect younger populations aged 20–49, posing significant challenges to global healthcare systems. Current research on early-onset CNS cancer trends is lim…
View article: Inhibiting autophagy selectively prunes dysfunctional tumor vessels and optimizes the tumor immune microenvironment
Inhibiting autophagy selectively prunes dysfunctional tumor vessels and optimizes the tumor immune microenvironment Open
Dysfunctional tumor vasculature, hypoxia, and an immunosuppressive microenvironment are significant barriers to effective cancer therapy. Autophagy, which is critical for maintaining cellular homeostasis and apoptosis resistance, is primar…
View article: The Potential of Immunotherapy for SMARCA4-Deficient Undifferentiated Uterine Sarcoma (SDUS)
The Potential of Immunotherapy for SMARCA4-Deficient Undifferentiated Uterine Sarcoma (SDUS) Open
(1) Background: SMARCA4-deficient undifferentiated uterine sarcoma (SDUS) is a rare and aggressive cancer that urgently requires novel therapeutic strategies. Despite the proven efficacy of immunotherapy in various cancer types, its applic…
View article: Case report: Diverse immune responses in advanced pancreatic ductal adenocarcinoma treated with immune checkpoint inhibitor-based conversion therapies
Case report: Diverse immune responses in advanced pancreatic ductal adenocarcinoma treated with immune checkpoint inhibitor-based conversion therapies Open
Pancreatic ductal adenocarcinoma (PDAC) is often diagnosed at an advanced stage, presenting limited therapeutic options and a grim prognosis due to its aggressive nature. Despite ongoing exploration of various combination therapies, a stan…
View article: Table S3 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma
Table S3 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma Open
Table S3 describes primer information for qPCR analysis.
View article: Supplemental Figure S3 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma
Supplemental Figure S3 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma Open
Supplemental Figure S3 describes that inhibiting nuclear translocation of NR4A2 hampers immunosuppressive functions and promotes antigen presentation capacities of microglia.
View article: Table S2 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma
Table S2 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma Open
Table S2 describes information of key research agents, data deposition and software versions.
View article: Supplemental Figure S5 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma
Supplemental Figure S5 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma Open
Supplemental Figure S5 describes that genetic knockout of Nr4a2 in microglia reverses immunosuppressive state.
View article: Supplemental Figure S4 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma
Supplemental Figure S4 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma Open
Supplemental Figure S4 describes that NR4A2-knockdown affects lipid metabolism and promotes antigen presentation of microglia.
View article: Data from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma
Data from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma Open
Glioblastoma (GBM) constitutes the most lethal primary brain tumor for which immunotherapy has provided limited benefit. The unique brain immune landscape is reflected in a complex tumor immune microenvironment (TIME) in GBM. Here, single-…
View article: Supplemental Figure S2 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma
Supplemental Figure S2 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma Open
Supplemental Figure S2 describes that oxidative stress in microglia promotes the immunosuppressive functions of microglia.
View article: Supplemental Figure S3 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma
Supplemental Figure S3 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma Open
Supplemental Figure S3 describes that inhibiting nuclear translocation of NR4A2 hampers immunosuppressive functions and promotes antigen presentation capacities of microglia.
View article: Supplemental Figure S1 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma
Supplemental Figure S1 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma Open
Supplemental Figure S1 describes elevated oxidative stress challenge in the microglia of glioma.
View article: Supplemental Figure S7 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma
Supplemental Figure S7 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma Open
Supplemental Figure S7 describes that oxidative stress in microglia as an independent predictor for clinical outcome in glioma patients.
View article: Supplemental Figure S6 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma
Supplemental Figure S6 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma Open
Supplemental Figure S6 describes that inhibition of NR4A2 or SQLE improves the therapeutic efficacy of immune checkpoint blockade.
View article: Table S1 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma
Table S1 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma Open
Table S1 describes glioma patients and tissue samples information for evaluating the relationship of oxidative stress in microglia and prognosis
View article: Table S4 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma
Table S4 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma Open
Table S4 describes list of literature-based immune marker panel selected to identity cell types of obtained clusters.
View article: Table S4 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma
Table S4 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma Open
Table S4 describes list of literature-based immune marker panel selected to identity cell types of obtained clusters.
View article: Table S2 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma
Table S2 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma Open
Table S2 describes information of key research agents, data deposition and software versions.
View article: Supplemental Figure S1 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma
Supplemental Figure S1 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma Open
Supplemental Figure S1 describes elevated oxidative stress challenge in the microglia of glioma.
View article: Supplemental Figure S5 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma
Supplemental Figure S5 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma Open
Supplemental Figure S5 describes that genetic knockout of Nr4a2 in microglia reverses immunosuppressive state.
View article: Supplemental Figure S7 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma
Supplemental Figure S7 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma Open
Supplemental Figure S7 describes that oxidative stress in microglia as an independent predictor for clinical outcome in glioma patients.
View article: Table S1 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma
Table S1 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma Open
Table S1 describes glioma patients and tissue samples information for evaluating the relationship of oxidative stress in microglia and prognosis
View article: Supplemental Figure S4 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma
Supplemental Figure S4 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma Open
Supplemental Figure S4 describes that NR4A2-knockdown affects lipid metabolism and promotes antigen presentation of microglia.
View article: Table S3 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma
Table S3 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma Open
Table S3 describes primer information for qPCR analysis.
View article: Supplemental Figure S2 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma
Supplemental Figure S2 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma Open
Supplemental Figure S2 describes that oxidative stress in microglia promotes the immunosuppressive functions of microglia.
View article: Supplemental Figure S6 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma
Supplemental Figure S6 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma Open
Supplemental Figure S6 describes that inhibition of NR4A2 or SQLE improves the therapeutic efficacy of immune checkpoint blockade.
View article: Supplemental Figure S2 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma
Supplemental Figure S2 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma Open
Supplemental Figure S2 describes that oxidative stress in microglia promotes the immunosuppressive functions of microglia.
View article: Supplemental Figure S1 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma
Supplemental Figure S1 from Targeting Microglial Metabolic Rewiring Synergizes with Immune-Checkpoint Blockade Therapy for Glioblastoma Open
Supplemental Figure S1 describes elevated oxidative stress challenge in the microglia of glioma.